Rituximab and Ianalumab develop B cell depletion differently: Rituximab is a first line choice for CD20-driven diseases like non-Hodgkin lymphoma or RA, while Ianalumab shows promise in broader B-cell depletion and BAFF-R inhibition, such as SLE or Sjögren’s disease.
![Figure 6 from the @wecrunchme first report titled "The Future is a Policy Choice". The figure is titled: "Figure 6: Estimated 2025 NIH funding per DALY [49,50] The left y-axis is titled “Funding ($) / DALY“. The x-axis has the names of selected diseases, Multiple Sclerosis, IBD, Rheumatoid Arthritis, Parkinson's Disease, ME/CFS, Asthma, Kidney Disease, Diabetes, Long COVID". Inset in the figure, “Long Covid and ME/CFS are underfunded to their disease burden, receiving $62 and $14 per DALY respectively“. Above each disease is a vertical bar that indicates the $’s/DALYS, with Long COVID and ME/CFS having the smallest amount of funding per disease burden measured by DALYs.](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:mjmkbp2ueuant5m5vrpsgkyq/bafkreifkmdz7bdj6rjputnjhfn43htwplky4qgzyov4yc5mxqlgfwu6y6y)
![Figure 4 from the @wecrunchme first report titled "The Future is a Policy Choice". The figure is titled: "Figure 4: US Disease burden of selected diseases [36]. The left y-axis is titled "DALYS". The x-axis has the names of selected diseases, Multiple Sclerosis, IBD, Rheumatoid Arthritis, Parkinson's Disease, ME/CFS, Asthma, Kidney Disease, Diabetes, Long COVID". Inset in the figure, "The estimated disease burden of Long Covid is comparable to diabetes". Above each disease is a vertical bar that indicates the number of DALYS, with diabetes and Long COVID having the same number of DALYS, which are greater than any other listed disease.](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:mjmkbp2ueuant5m5vrpsgkyq/bafkreihjiz5jzsnegltosy5gfelamxlgjluqgvqhzmiclnoffilfh7eehu)
